114 related articles for article (PubMed ID: 22130178)
1. Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder.
Seo JS; Jamieson K; Cosgrove V; Gwizdowski IS; Yang H; Sheehan DV; McElroy SL; Suppes T
Eur Psychiatry; 2013 Mar; 28(3):190-6. PubMed ID: 22130178
[TBL] [Abstract][Full Text] [Related]
2. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder.
Suppes T; McElroy SL; Sheehan DV; Hidalgo RB; Cosgrove VE; Gwizdowski IS; Feldman NS
J Clin Psychiatry; 2014 Jan; 75(1):77-84. PubMed ID: 24345758
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review.
Gao K; Muzina D; Gajwani P; Calabrese JR
J Clin Psychiatry; 2006 Sep; 67(9):1327-40. PubMed ID: 17017818
[TBL] [Abstract][Full Text] [Related]
5. Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient.
Sheehan DV; Harnett-Sheehan K; Hidalgo RB; Janavs J; McElroy SL; Amado D; Suppes T
J Affect Disord; 2013 Feb; 145(1):83-94. PubMed ID: 22920718
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study.
Brawman-Mintzer O; Knapp RG; Nietert PJ
J Clin Psychiatry; 2005 Oct; 66(10):1321-5. PubMed ID: 16259547
[TBL] [Abstract][Full Text] [Related]
7. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
Hirschfeld RM; Weisler RH; Raines SR; Macfadden W;
J Clin Psychiatry; 2006 Mar; 67(3):355-62. PubMed ID: 16649820
[TBL] [Abstract][Full Text] [Related]
8. An open-label trial of risperidone augmentation for refractory anxiety disorders.
Simon NM; Hoge EA; Fischmann D; Worthington JJ; Christian KM; Kinrys G; Pollack MH
J Clin Psychiatry; 2006 Mar; 67(3):381-5. PubMed ID: 16649823
[TBL] [Abstract][Full Text] [Related]
9. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.
Hirschfeld RM; Keck PE; Kramer M; Karcher K; Canuso C; Eerdekens M; Grossman F
Am J Psychiatry; 2004 Jun; 161(6):1057-65. PubMed ID: 15169694
[TBL] [Abstract][Full Text] [Related]
10. An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.
Hirschfeld RM; Eerdekens M; Kalali AH; Canuso CM; Khan AA; Karcher K; Palumbo JM
Int Clin Psychopharmacol; 2006 Jan; 21(1):11-20. PubMed ID: 16317312
[TBL] [Abstract][Full Text] [Related]
11. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.
Haas M; Delbello MP; Pandina G; Kushner S; Van Hove I; Augustyns I; Quiroz J; Kusumakar V
Bipolar Disord; 2009 Nov; 11(7):687-700. PubMed ID: 19839994
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial.
Pandina GJ; Canuso CM; Turkoz I; Kujawa M; Mahmoud RA
Psychopharmacol Bull; 2007; 40(3):41-57. PubMed ID: 18007568
[TBL] [Abstract][Full Text] [Related]
13. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.
Prosser JM; Yard S; Steele A; Cohen LJ; Galynker II
BMC Psychiatry; 2009 May; 9():25. PubMed ID: 19470174
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
Macfadden W; Alphs L; Haskins JT; Turner N; Turkoz I; Bossie C; Kujawa M; Mahmoud R
Bipolar Disord; 2009 Dec; 11(8):827-39. PubMed ID: 19922552
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy.
Gopal S; Steffens DC; Kramer ML; Olsen MK
J Clin Psychiatry; 2005 Aug; 66(8):1016-20. PubMed ID: 16086617
[TBL] [Abstract][Full Text] [Related]
16. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Sachs GS; Grossman F; Ghaemi SN; Okamoto A; Bowden CL
Am J Psychiatry; 2002 Jul; 159(7):1146-54. PubMed ID: 12091192
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders.
Keck PE; Strawn JR; McElroy SL
J Clin Psychiatry; 2006; 67 Suppl 1():8-15. PubMed ID: 16426111
[TBL] [Abstract][Full Text] [Related]
18. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study.
Khanna S; Vieta E; Lyons B; Grossman F; Eerdekens M; Kramer M
Br J Psychiatry; 2005 Sep; 187():229-34. PubMed ID: 16135859
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.
Perlis RH; Baker RW; Zarate CA; Brown EB; Schuh LM; Jamal HH; Tohen M
J Clin Psychiatry; 2006 Nov; 67(11):1747-53. PubMed ID: 17196055
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
